Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Curr Mol Med ; 11(8): 686-95, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21902650

ABSTRACT

The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.


Subject(s)
Neoplasms/drug therapy , ran GTP-Binding Protein/metabolism , GTP Phosphohydrolases/antagonists & inhibitors , GTP Phosphohydrolases/metabolism , Humans , Molecular Targeted Therapy , Neoplasms/enzymology , Signal Transduction , ran GTP-Binding Protein/antagonists & inhibitors
2.
Oncogene ; 29(5): 752-62, 2010 Feb 04.
Article in English | MEDLINE | ID: mdl-19901966

ABSTRACT

Osteopontin is a secreted, integrin-binding and phosphorylated acidic glycoprotein, which has an important role in tumour progression. We have shown that Wnt, Ets, AP-1, c-jun and beta-catenin/Lef-1/Tcf-1 stimulates OPN transcription in rat mammary carcinoma cells by binding to a specific promoter sequence. However, co-repressors of OPN have not been identified. In this study, we have used the bacterial two-hybrid system to isolate cDNA-encoding proteins that bind to OPN and modulate its role in malignant transformation. Using this approach we isolated interferon-induced transmembrane protein 3 gene (IFITM3) as a potential protein partner. We show that IFITM3 and OPN interact in vitro and in vivo and that IFITM3 reduces osteopontin (OPN) mRNA expression, possibly by affecting OPN mRNA stability. Stable transfection of IFITM3 inhibits OPN, which mediates anchorage-independent growth, cell adhesion and cell invasion. Northern blot analysis revealed an inverse mRNA expression pattern of IFITM3 and OPN in human mammary cell lines. Inhibition of IFITM3 by antisense RNA promoted OPN protein expression, enhanced cell invasion by parental benign non-invasive Rama 37 cells, indicating that the two proteins interact functionally as well. We also identified an IFITM3 DNA-binding domain, which interacts with OPN, deletion of which abolished its inhibitive effect on OPN. This work has shown for the first time that IFITM3 physically interacts with OPN and reduces OPN mRNA expression, which mediates cell adhesion, cell invasion, colony formation in soft agar and metastasis in a rat model system.


Subject(s)
Breast Neoplasms/metabolism , Gene Expression Regulation, Neoplastic/physiology , Membrane Proteins/metabolism , Osteopontin/metabolism , RNA-Binding Proteins/metabolism , Animals , Blotting, Northern , Blotting, Western , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Adhesion/physiology , Cell Line, Tumor , Cell Movement/physiology , Female , Humans , Immunoprecipitation , Neoplasm Invasiveness/genetics , Osteopontin/genetics , Promoter Regions, Genetic , RNA, Messenger/analysis , Rats
3.
Oncogene ; 27(57): 7139-49, 2008 Dec 04.
Article in English | MEDLINE | ID: mdl-18794800

ABSTRACT

Osteopontin (OPN) is a phosphorylated glycoprotein that binds to alpha v-containing integrins and is important in malignant transformation and cancer. Previously, we have utilized suppressive subtractive hybridization between mRNAs isolated from the Rama 37 (R37) rat mammary cell line and a subclone rendered invasive and metastatic by stable transfection with an expression vector for OPN to identify RAN GTPase (RAN) as the most overexpressed gene, in addition to that of OPN. Here we show that transfection of noninvasive R37 cells with an expression vector for RAN resulted in increased anchorage-independent growth, cell attachment and invasion through Matrigel in vitro, and metastasis in syngeneic rats. This induction of a malignant phenotype was induced independently of the expression of OPN, and was reversed by specifically reducing the expression of RAN using small-interfering RNAs. By using a combination of mutant protein and inhibitors, it was found that RAN signal transduction occurred through the c-Met receptor and PI3 kinase. This study therefore identifies RAN as a novel effector of OPN-mediated malignant transformation and some of its downstream signaling events in a mammary epithelial model of cancer invasion/metastasis.


Subject(s)
Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/metabolism , Neoplasm Invasiveness/genetics , Osteopontin/metabolism , ran GTP-Binding Protein/metabolism , Animals , Blotting, Northern , Blotting, Western , Cell Line, Tumor , Cell Proliferation , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Female , Fluorescent Antibody Technique , Gene Expression , Immunohistochemistry , Osteopontin/genetics , Phenotype , Phosphatidylinositol 3-Kinases/biosynthesis , Proto-Oncogene Proteins c-met/biosynthesis , RNA, Small Interfering , Rats , Signal Transduction/physiology , Transfection , ran GTP-Binding Protein/genetics
4.
Oncogene ; 20(14): 1793-7, 2001 Mar 29.
Article in English | MEDLINE | ID: mdl-11313926

ABSTRACT

Small 1000 bp fragments of DNA derived from human malignant breast cancer cells have been isolated which, when transfected into a benign rat mammary cell line induce the production of osteopontin and thereby endow those cells with the capability to metastasize in syngeneic rats. Using transient transfections of an osteopontin promoter-reporter construct, we have now identified the active moiety in the metastasis-inducing DNA as the binding site for the T cell factor (Tcf) family of transcription factors and located Tcf-4, beta-catenin and E-cadherin in the relevant DNA complex in vitro. The regulatory effects of the metastasis-inducing DNAs are therefore exerted, at least in part, by a CAAAG sequence which can sequester Tcf-4, thereby promoting transcription of the direct effector for metastasis in this system, osteopontin.


Subject(s)
DNA, Neoplasm/metabolism , Neoplasm Metastasis/genetics , Sialoglycoproteins/genetics , Transcription Factors/metabolism , Animals , Binding Sites , DNA, Neoplasm/chemistry , Osteopontin , Promoter Regions, Genetic , Rats , TCF Transcription Factors , Transcription Factor 7-Like 2 Protein , Transfection
6.
Mol Endocrinol ; 11(7): 928-37, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9178752

ABSTRACT

Transient transfection experiments in which three different estrogen response element-containing reporter genes were cotransfected into HeLa cells, together with constitutively expressed estrogen receptor (ER) constructs, demonstrate that activation of the transcription of the reporter genes by epidermal growth factor (EGF) and by cholera toxin with 3-isobutyl-1-methyl-xanthine, which elevate cellular cAMP, is dependent upon the presence of functional ER. Cotransfection of the reporter genes with truncated versions of the ER shows that the two non-ligand activators of ER require different regions of the receptor to produce their effects on transcription. EGF acts primarily by means of transactivation domain AF-1, whereas cAMP acts via transactivation domain AF-2 of the ER. A point mutation that removes a major site of inducible phosphorylation within the AF-1 domain of the ER abolishes the response to EGF, but the response to estradiol and cAMP is retained. Specific inhibition of cAMP-activated protein kinase (protein kinase A) prevents the response to elevated cAMP but does not affect EGF or estradiol responses. Overexpression of the protein kinase A catalytic subunit in HeLa cells results in an amplified response to estradiol, similar to that induced by cholera toxin with 3-isobutyl-1-methyl-xanthine. Comparable experiments performed using COS-1 cells produce similar results but also reveal cell type- and promoter-specific aspects of the activation mechanisms. Apparently, the ER may be activated by three different signal molecules, estradiol, EGF, and cAMP, each using a mechanism that is distinguishable from that of the others.


Subject(s)
Gene Expression Regulation, Developmental/genetics , Genes, Reporter/genetics , Promoter Regions, Genetic/genetics , Receptors, Estrogen/genetics , Sulfonamides , Transcriptional Activation/genetics , 1-Methyl-3-isobutylxanthine/pharmacology , Animals , COS Cells , Cyclic AMP/pharmacology , Cyclic AMP-Dependent Protein Kinases/genetics , Enzyme Inhibitors/pharmacology , Epidermal Growth Factor/pharmacology , Estradiol/pharmacology , Gene Expression Regulation, Developmental/drug effects , Genes, Reporter/drug effects , HeLa Cells , Humans , Isoquinolines/pharmacology , Point Mutation/genetics , Promoter Regions, Genetic/drug effects , Receptors, Estrogen/drug effects , Transcriptional Activation/drug effects , Transfection/genetics
7.
J Steroid Biochem Mol Biol ; 60(5-6): 269-76, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9219917

ABSTRACT

The response of two endogenous, estrogen-induced genes, LIV-1 and pS2, to growth factor stimulation of MCF-7 cells was examined. Epidermal growth factor (EGF), transforming growth factor alpha (TGF alpha) and insulin-like growth factor-1 (IGF-1) were each able to induce an increase in the two mRNAs in the absence of estradiol, and their effects were additive to that of an optimally inducing concentration (10(-8) M) of the hormone. Induction by EGF and TGF alpha, but not by IGF-1, were also additive to induction by a saturating concentration (2 microg/ml) of insulin. TGFbeta, an antimitogenic growth factor for MCF-7 cells, did not induce LIV-1 or pS2 mRNA but inhibited induction by estradiol. Increases in mRNA were shown to reflect increases in specific gene transcription. Induction by growth factors, but not by estradiol, was dependent upon protein synthesis. Induction by both growth factors and estradiol was inhibited by the pure antiestrogen, ICI 164384 (ICI), and by the mixed agonist/antagonist, tamoxifen. Despite differences in patterns of expression in vivo and in vitro, both LIV-1 and pS2 appeared to be responsive to growth factors via a mechanism distinct from that of estradiol but requiring the estrogen receptor.


Subject(s)
Breast Neoplasms/genetics , Gene Expression Regulation, Neoplastic , Growth Substances/pharmacology , Peptides/pharmacology , Proteins , Epidermal Growth Factor/pharmacology , Female , Humans , Insulin-Like Growth Factor I/pharmacology , Neoplasm Proteins/biosynthesis , Protein Biosynthesis , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Transforming Growth Factor alpha/pharmacology , Trefoil Factor-1 , Tumor Cells, Cultured , Tumor Suppressor Proteins
8.
Mol Cell Endocrinol ; 124(1-2): 71-7, 1996 Nov 29.
Article in English | MEDLINE | ID: mdl-9027326

ABSTRACT

The mRNA levels of LIV-1 and pS2, two estrogen-responsive genes, are increased by the agents, cholera toxin (CT) plus 3-isobutyl-l-methylxanthine (IBMX), which cause an increase in cAMP in MCF-7 human breast cancer cells. The simultaneous addition of estradiol and CT/IBMX results in a synergistic induction of the two mRNAs. The changes in mRNA reflect changes in transcription of the two genes. Interestingly, the addition of CT/IBMX to estradiol not only causes a greater increase in transcription rate but the increase is longer-lasting that seen with the hormone alone. Stimulation of mRNA levels by CT/IBMX, but not by estradiol, was prevented by cycloheximide. Stimulation by both estradiol and by CT/IBMX was prevented by the antiestrogen, ICI 164387. Transcription of LIV-1 and pS2 genes is by both estradiol and cAMP, via separate mechanisms both requiring the estrogen receptor.


Subject(s)
Cyclic AMP/physiology , Estradiol/pharmacology , Gene Expression Regulation, Neoplastic/physiology , Neoplasm Proteins/genetics , Proteins , 1-Methyl-3-isobutylxanthine/pharmacology , Breast Neoplasms , Carcinoma , Cholera Toxin/pharmacology , Cycloheximide/pharmacology , Estradiol/analogs & derivatives , Estrogen Antagonists/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Humans , Phosphodiesterase Inhibitors/pharmacology , Polyunsaturated Alkamides , Protein Synthesis Inhibitors/pharmacology , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Receptors, Estradiol/physiology , Trefoil Factor-1 , Tumor Cells, Cultured , Tumor Suppressor Proteins
11.
Mol Cell Endocrinol ; 121(1): 29-35, 1996 Jul 23.
Article in English | MEDLINE | ID: mdl-8865163

ABSTRACT

Estrogen responses of human breast cancer cell lines have frequently been shown to be promoted by insulin. We have examined the action of insulin, and its interaction with estradiol, in regulating the expression of the estrogen-induced genes, LIV-1 and pS2. Both hormones cause increases in mRNA levels of the two genes but do so by distinct mechanisms. The concentration of insulin required to produce this effect suggests that it is acting via its ability to bind to the IGF-1 receptor. Both insulin and estradiol exert their effects at the level of transcription. Induction by insulin is dependent upon continued protein synthesis whereas induction by estradiol is not. Induction by both insulin and estradiol is prevented by the pure antiestrogen. ICI 164384, indicating the requirement for an activatable estrogen receptor. Insulin does not stimulate LIV-1 expression via the androgen receptor. These results demonstrate that both estradiol and insulin can stimulate the transcription of these estrogen-inducible genes, by separate mechanisms both of which involve the estrogen receptor.


Subject(s)
Estradiol/pharmacology , Gene Expression Regulation , Insulin-Like Growth Factor I/pharmacology , Neoplasm Proteins/genetics , Proteins , Cycloheximide/pharmacology , Dihydrotestosterone/pharmacology , Dose-Response Relationship, Drug , Estradiol/analogs & derivatives , Estrogen Antagonists/pharmacology , Humans , Insulin/pharmacology , Polyunsaturated Alkamides , Protein Synthesis Inhibitors/pharmacology , RNA, Messenger , Trefoil Factor-1 , Tumor Cells, Cultured , Tumor Suppressor Proteins
13.
Mol Cell Endocrinol ; 111(1): 75-81, 1995 Apr 28.
Article in English | MEDLINE | ID: mdl-7649356

ABSTRACT

The level of oestrogen-responsive gene expression in breast tumours has been proposed as a predictor of the response of the tumour to endocrine (anti-oestrogen) therapy. We demonstrate that different oestrogen-responsive genes may differ in their responses to other hormones. pLIV-1 and pS2 are two oestrogen-regulated genes that are expressed in the MCF-7 human breast cancer cell line. We show that pLIV-1 mRNA, but not pS2 mRNA, is also induced, to a lesser extent, by progesterone, 5 alpha-dihydrotestosterone and dexamethasone. For pLIV-1, combinations of these hormones with oestradiol and with the pure anti-oestrogen, ICI 164384, indicate that the mechanism of its response to these other steroid hormones is clearly separable from its response to oestrogen. Such behaviour in breast tumours in vivo could explain the lack of absolute correlation between marker gene expression and anti-oestrogen sensitivity and between the expression of individual marker genes.


Subject(s)
Breast Neoplasms/metabolism , Estrogens/pharmacology , Gene Expression Regulation, Neoplastic/genetics , Gene Expression/drug effects , Hormones/pharmacology , Dexamethasone/pharmacology , Dihydrotestosterone/pharmacology , Drug Synergism , Estradiol/analogs & derivatives , Estradiol/pharmacology , Estrogen Antagonists/pharmacology , Humans , Polyunsaturated Alkamides , Progesterone/pharmacology , RNA, Messenger/biosynthesis , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...